"Alzheimer's breakthrough restores 2 hours of sleep"? It was in mice
- Claim
- ALZHEIMER'S SLEEP BREAKTHROUGH?
- Catch
- MICE, NOT PEOPLE
- Verdict
- A REAL CLUE, NOT A CURE
Headlines called it a "mind-blowing" Alzheimer's breakthrough. The study, from the University of Kentucky's Sanders-Brown Center on Aging and published in Alzheimer's & Dementia (2026), used mice genetically prone to amyloid plaques. Their non-REM (deep) sleep was disrupted early, by 6 months of age, and did not worsen by 18 months even though plaque burden more than doubled. Normal aging mainly reduced REM sleep instead. When the researchers depleted about 87% of microglia, the brain's immune cells, using the drug pexidartinib (PLX3397) in food for 14 days, the mice regained more than two hours of sleep per day, with longer non-REM periods, without any reduction in plaques. The authors conclude that the microglial response to plaques, rather than the plaques alone, drives the sleep loss. The catch: this was in mice, not people. Microglia also have protective jobs, so wiping them out is not a treatment. Pexidartinib (Turalio) is FDA-approved only for a rare joint tumor, tenosynovial giant cell tumor, and carries a boxed warning for serious and potentially fatal liver injury. Gentler ways to adjust microglia are still experimental.
SOURCES
- Constantino, Macauley et al. (2026), "Early microglial response to amyloid plaques drives sleep loss in Alzheimer's disease," Alzheimer's & Dementia. DOI: 10.1002/alz.71579
- US FDA, Turalio (pexidartinib) approval and prescribing information (boxed warning: hepatotoxicity)
For information only, not medical advice. If someone you care for has Alzheimer's and sleep problems, talk to their doctor.
